PTC Therapeutics (PTCT) Misses Q4 EPS by $1.41, Offers Guidance

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($1.67), $1.41 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $164.7 million versus the consensus estimate of $256.93 million.

GUIDANCE:

PTC Therapeutics sees FY2026 revenue of $700-800 million, versus the consensus of $990.3 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI